SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma’s arm gets 3 observations from USFDA for Telangana API facility

15 Dec 2025 Evaluate

The United States Food and Drug Administration (USFDA) has inspected Aurobindo Pharma’s wholly owned subsidiary -- Apitoria Pharma’s API manufacturing facility - Unit-V situated at Sangareddy district in Telangana. The inspection was conducted from December 1 to December 12, 2025. The USFDA has issued ‘Form 483’ with total of 3 observations which are procedural in nature.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1587.80 -6.10 (-0.38%)
07-Jul-2026 14:53 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1903.95
Dr. Reddys Labs. 1355.90
Cipla 1456.60
Zydus Lifesciences 1154.40
Lupin 2487.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: